TY  - GEN
AU  - Roux,C
AU  - Hofbauer,L C
AU  - Ho,P R
AU  - Wark,J D
AU  - Zillikens,M C
AU  - Fahrleitner-Pammer,A
AU  - Hawkins,F
AU  - Micaelo,M
AU  - Minisola,S
AU  - Papaioannou,N
AU  - Stone,M
AU  - Ferreira,I
AU  - Siddhanti,S
AU  - Wagman,R B
AU  - Brown,J P
TI  - Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study
SN  - 1873-2763
PY  - 2014///0831
KW  - Aged
KW  - Alendronate
KW  - therapeutic use
KW  - Antibodies, Monoclonal, Humanized
KW  - adverse effects
KW  - Bone Density
KW  - drug effects
KW  - Bone Density Conservation Agents
KW  - Collagen Type I
KW  - blood
KW  - Demography
KW  - Denosumab
KW  - Etidronic Acid
KW  - analogs & derivatives
KW  - Female
KW  - Humans
KW  - Medication Adherence
KW  - Osteoporosis, Postmenopausal
KW  - Peptides
KW  - Risedronic Acid
KW  - Treatment Outcome
N1  - Publication Type: Comparative Study; Journal Article; Randomized Controlled Trial; Research Support, Non-U.S. Gov't
UR  - https://doi.org/10.1016/j.bone.2013.10.006
ER  -